Contacts

MedinCell announces the initiation of coverage of its stock by Portzamparc – BNP Paribas Group 

March 28, 2023

• Entitled “Liberating blockbusters over the long term“, the Portzamparc – BNP Paribas Group report recommends the stock as a buy with a target price of €14.4 per share. 

This new coverage comes as the first product based on MedinCell’s long-acting injectable technology is expected to be commercialized in the U.S. in the first half of 2023 (subject to FDA approval); two other products are in Phase 3, with several others in development. 

MedinCell was recently awarded “Prime” status by ISS ESG for its sustainability performance, placing it in the top 10% of companies in the pharmaceutical and biotech industry. 

MedinCell is also covered by Bryan Garnier, Kepler Cheuvreux, ODDO-BHF and TP ICAP. 

Session en français

Mardi 19 décembre, 18h30 : Présentation des résultats du premier semestre de l'année fiscale 2023-24

English session

Tuesday, December 19, 6:30 pm: Half-year earnings call (April 1st - September 30th)

Êtes-vous un actionnaire de MedinCell ? / Are you a MedinCell shareholder?
Vous êtes / You are :
This field is for validation purposes and should be left unchanged.

CONTACT

  • This field is for validation purposes and should be left unchanged.